UCB Biopharma

Part of UCB (GLEIF)

CompanyBelgium

UCB Biopharma develops 2 assets, the furthest approved (romosozumab in osteoporosis). Mostly antibody acting on SOST; based in Belgium.

2
Assets
Furthest: Approved; 3
Trials: 2
Signals

Pipeline

2

romosozumab
Inhibits sclerostin to promote bone formation and reduce bone resorption
Approved, Antibody, SOST, osteoporosis, osteogenesis imperfecta (Phase 3)
Galvokimig
Phase 2, Antibody, chronic obstructive pulmonary disease with chronic bronchitis

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials3
Signals2
Similar companies6

Updated 13 Oct 2026 · 21 sources